Scarica l'app Stockscreener
67.77
1.43%
-0.98
Dopo l'orario di chiusura:
67.77
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTCT Giù?
Forum
Previsione
Precedente Chiudi:
$68.75
Aprire:
$67.32
Volume 24 ore:
482.70K
Relative Volume:
0.40
Capitalizzazione di mercato:
$5.61B
Reddito:
$1.73B
Utile/perdita netta:
$682.64M
Rapporto P/E:
8.7599
EPS:
7.7364
Flusso di cassa netto:
$411.18M
1 W Prestazione:
+1.15%
1M Prestazione:
+2.11%
6M Prestazione:
+7.54%
1 anno Prestazione:
+40.11%
Intervallo 1D:
$67.04
$68.70
Intervallo di 1 settimana:
$64.37
$70.39
Portata 52W:
$35.95
$87.50
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Nome
Ptc Therapeutics Inc
Settore
Industria
Telefono
(908) 222-7000
Indirizzo
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
67.77 | 5.61B | 1.73B | 682.64M | 411.18M | 7.7364 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-12-01 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-06-17 | Iniziato | Truist | Buy |
| 2025-05-09 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-05-07 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-03-11 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Iniziato | Scotiabank | Sector Perform |
| 2024-12-13 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-09-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-08-26 | Ripresa | UBS | Buy |
| 2024-05-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-10-30 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Downgrade | Citigroup | Neutral → Sell |
| 2023-10-06 | Downgrade | Truist | Buy → Hold |
| 2023-09-18 | Downgrade | Citigroup | Buy → Neutral |
| 2023-09-15 | Downgrade | Raymond James | Outperform → Underperform |
| 2023-03-17 | Iniziato | SVB Securities | Market Perform |
| 2022-12-14 | Iniziato | Goldman | Sell |
| 2022-09-12 | Iniziato | Jefferies | Buy |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-29 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-11-30 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-04-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-05-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Iniziato | Bernstein | Outperform |
| 2018-10-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-06-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Downgrade | JP Morgan | Neutral → Underweight |
Mostra tutto
Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie
How The PTC Therapeutics (PTCT) Story Is Shifting With Sephience And DMD Uncertainty - finance.yahoo.com
Almstead, PTC Therapeutics officer, sells $3.59 million in shares By Investing.com - Investing.com Canada
PTC Therapeutics (NASDAQ:PTCT) Insider Neil Gregory Almstead Sells 52,003 Shares - MarketBeat
PTC Therapeutics (PTCT) officer sells 52,003 shares under 10b5-1 plan - Stock Titan
PTCT (NASDAQ: PTCT) lists 829 vested shares for resale; insider sales detailed - Stock Titan
PTC Therapeutics, Inc. (PTCT) Stock forecasts - Yahoo Finance UK
Insiders sell shares at PTCT (NASDAQ: PTCT) under Rule 144, multiple trades - Stock Titan
(PTCT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Jefferies Downgrades PTC Therapeutics (PTCT) to 'Hold' with Pric - GuruFocus
PTC Therapeutics Inc (PTCT) Stock Price Quote Today & Current Price Chart - Capital.com
PTC Therapeutics, Inc. (PTCT) Latest Stock News & Headlines - Yahoo Finance
PTC Therapeutics (NASDAQ:PTCT) Earns "Hold" Rating from Jefferies Financial Group - MarketBeat
Jefferies Initiates PTC Therapeutics(PTCT.US) With Hold Rating, Announces Target Price $76 - Moomoo
PTC Therapeutics, Inc. $PTCT Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Jefferies downgrades PTC Therapeutics (PTCT) - MSN
Is It Time To Reassess PTC Therapeutics (PTCT) After Mixed Multi Year Share Performance? - Sahm
PTC Therapeutics Inc (PTCT) Stock Price, Trades & News - GuruFocus
Vanguard disaggregates holdings; reports 0 PTC Therapeutics shares (PTCT) - Stock Titan
PTC Therapeutics (PTCT) director receives new stock and option awards - Stock Titan
New PTC Therapeutics (PTCT) director Jessica Chutter files initial Form 3 - Stock Titan
PTC Therapeutics (NASDAQ:PTCT) Rating Updates Drive Nasdaq Futures Focus - Kalkine Media
PTC Therapeutics (NASDAQ:PTCT) Upgraded at Truist Financial - MarketBeat
A Look At PTC Therapeutics (PTCT) Valuation As Shares Reflect Mixed Recent Returns - Sahm
PTC Therapeutics adds Jessica Chutter to board of directors By Investing.com - Investing.com India
PTCT SEC FilingsPtc Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
PTC Therapeutics Adds Veteran Banker to Board - TipRanks
PTC Therapeutics Appoints Jessica Chutter To Board - citybiz
Ptc Therapeutics appoints biotech banking pioneer Jessica Chutter to board of directors - marketscreener.com
Ptc Therapeutics, Inc. Appoints Jessica Chutter to Board of Directors, Effective from March 24, 2026 - MarketScreener
PTC Therapeutics appoints Jessica Chutter to its board - TradingView
Biotech banker Jessica Chutter joins PTC Therapeutics (NASDAQ: PTCT) board - Stock Titan
PTC Therapeutics adds Jessica Chutter to board of directors - Investing.com
PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors - Yahoo Finance
SG Americas Securities LLC Has $67.94 Million Stock Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Gains Attention After Rating Updates - Kalkine Media
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
JPMorgan Chase & Co. Trims Stock Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz - The National Law Review
Assessing PTC Therapeutics (PTCT) Valuation As Rare Disease Growth And Sephience Execution Shape Expectations - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating PTC Therapeut - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
PTC Therapeutics or Eli Lilly: Which Stock Has More Upside? - Trefis
Between PTC Therapeutics and Eli Lilly, Which Stock Looks Set to Break Out? - Trefis
Fundamentals Check: How sensitive is PTC Therapeutics Inc to inflationPortfolio Return Report & Accurate Intraday Trading Signals - baoquankhu1.vn
Cinctive Capital Management LP Takes Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Boxer Capital Management LLC Invests $12.27 Million in PTC Therapeutics, Inc. $PTCT - MarketBeat
What PTC Therapeutics (PTCT)'s FDA Leadership Shift Means For Its Gene and RNA Pipeline Narrative - simplywall.st
Matthew Klein Sells 2,662 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GuruFocus
PTC Therapeutics (PTCT) CEO logs RSU vesting and automatic tax share sale - Stock Titan
18 new PTC Therapeutics hires receive stock options, RSUs - Stock Titan
Ptc Therapeutics Inc Azioni (PTCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):